Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR4 | P46093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285974 | 0.92 | GPR119 (0.43) | GPR119USP2SMN1; SMN2GPR4 | |
| SCHEMBL13131365 | 0.88 | GPR119 (0.43) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL13805598 | 0.85 | GPR119 (0.42) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL15742942 | 0.84 | GPR119 (0.41) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL14996535 | 0.84 | GPR119 (0.41) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL485273 | 0.83 | GPR119 (0.41) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL15076623 | 0.83 | USP2 (0.45) | GPR119USP2SMN1; SMN2GPR4 | |
| SCHEMBL2793698 | 0.82 | GPR119 (0.40) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL13234469 | 0.82 | GPR119 (0.41) | GPR119USP2SMN1; SMN2 | |
| SCHEMBL4973467 | 0.81 | MEN1 (0.48) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524852-B2 | Bicyclic pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| EP-1552842-A1 | BICYCLIC PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037834-A1 | Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection | CX3CR1, CCL5, CCRL2 | GPR119 783/4885USP2 4807/4885SMN1; SMN2 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.